Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03681275 · ClinicalTrials.gov registry record · Phase 2
Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction
A Phase 2 study of Diaphragm Injury, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT03681275: Recruiting Phase 2 study of Diaphragm Injury, sponsored by Stanford University.
NCT03681275 is a Phase 2 study of Diaphragm Injury that is actively recruiting participants, run by Stanford University. The registered enrollment target is 70 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03681275, a Phase 2 study of Diaphragm Injury, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.
Primary Outcome
Change in the force deficit that develops between the first and second muscle biopsies in the drug-treated vs. placebo groups
Conditions Studied
Interventions
- DRUG Tofacitinib 10 MG [Xeljanz]
- DRUG Placebo to match Tofacitinib
Study Locations (1)
California
- Stanford University Medical Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2019-09-03 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 2 |
What NCT03681275 shows while recruiting
NCT03681275 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Diaphragm Injury appearing as the primary indexed condition, and to 2 interventions - of which Tofacitinib 10 MG [Xeljanz] is the first listed.
NCT03681275 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03681275 about?
NCT03681275 is a clinical study titled "Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction". We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of...
What is the current status of trial NCT03681275?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2019-09-03. Estimated completion is 2026-11-30.
What conditions does trial NCT03681275 study?
This clinical trial studies the following conditions: Diaphragm Injury.
What interventions are being tested in trial NCT03681275?
The interventions under investigation include: Tofacitinib 10 MG [Xeljanz] (DRUG), Placebo to match Tofacitinib (DRUG).
Who is sponsoring clinical trial NCT03681275?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03681275 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diaphragm Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03681275's enrollment target sits among peer trials
70 937th of 2000 higher than 1,036 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI